布地奈德福莫特罗粉吸入剂联合血必净治疗慢性阻塞性肺疾病患者的临床研究  

Clinical trial of budesonide formoterol powder inhaler combined with Xuebijing on patients with chronic obstructive pulmonary disease

作　　者：张子洲[1] 钱璞[1] 沈科 ZHANG Zi-zhou;QIAN Pu;SHEN Ke(Department of Respiratory Medicine, Seventh People's Hospital of Changzhou, Changzhou 213011,Jiangsu Province, China)

机构地区：[1]常州市第七人民医院呼吸内科,江苏常州213011

出　　处：《中国临床药理学杂志》2019年第1期10-13,共4页The Chinese Journal of Clinical Pharmacology

基　　金：江苏省科技计划基金资助项目(BL201223)

摘　　要：目的观察布地奈德福莫特罗粉吸入剂联合血必净治疗慢性阻塞性肺疾病(COPD)患者的临床疗效和安全性。方法将92例COPD患者随机分为试验组和对照组,每组46例。对照组给予布地奈德福莫特罗粉吸入剂治疗,每次1～2吸,每天2次,当每天2次可控制临床症状时,可减少剂量为每天1次。试验组在对照组的基础上给予血必净注射液40 m L,加入5%葡萄糖注射液100m L中,静脉滴注,每天2次。2组均治疗8周。比较2组患者的临床疗效,观察2组肺功能、血清白细胞介素(IL)-17A、趋化因子CXCL12、s E-SLT、C反应蛋白(CRP)、IL-6、呼吸困难评分(m MRC)及药物不良反应发生情况。结果治疗后,试验组和对照组的总有效率分别为89. 13%(41例/46例),69. 57%(32例/46例),差异有统计学意义(P <0. 05)。治疗后,试验组第1秒用力呼出量(FEV1)、FEV1/用力肺活量(FVC)分别为(2. 33±0. 52) L,(64. 41±6. 93)%,对照组分别为(2. 00±0. 25) L,(55. 73±5. 44)%,差异均有统计学意义(均P <0. 05);试验组血清IL^(-1)7A、CXCL12、s E-SLT、CRP、IL-6分别为(23. 75±3. 35) pg·m L^(-1),(173. 68±12. 99) pg·m L^(-1),(16. 88±1. 19)μg·L^(-1),(8. 20±1. 18) mg·L^(-1),(9. 48±2. 22) pg·m L^(-1),对照组分别为(35. 02±3. 40) pg·m L^(-1),(192. 41±18. 21) pg·m L^(-1),(20. 49±1. 95)μg·L^(-1),(12. 32±8. 20) mg·L^(-1),(14. 97±2. 01) pg·m L^(-1),差异均有统计学意义(均P <0. 05)。试验组m MRC评分为(1. 00±0. 37)分,对照组为(1. 93±0. 25)分,差异有统计学意义(P <0. 05)。治疗期间,试验组出现心悸1例,头痛2例,恶心呕吐2例及失眠1例,药物不良反应发生率为13. 04%(6例/46例);对照组出现心悸2例,头痛2例,药物不良反应发生率为8. 70%(4例/46例),差异无统计学意义(P> 0. 05)。结论布地奈德福莫特罗粉吸入剂联合血必净治疗可以改善COPD患者临床疗效,安全可靠。Objective To observe the clinical effect and safety of budesonide formoterol powder inhaler combined with Xuebijing in the treatment of patients with chronic obstructive pulmonary disease(COPD).Methods Ninety-two patients with COPD were randomly divided into treamtent group and control group,each group 46 patients.Control group was given budesonide formoterol powder inhalation 1-2 suction a time,2 times a day,if 2 times a day can control clinical symptoms,can reduce the dose to 1 time a day.Treatment group was given Xuebijing injection40 mL,added to 5% glucose injection 100 mL,intravenously,on thebasis of control group.All patients were treated for 8 weeks.The clinical efficacy,and the changes of lung function,serum interleukin(IL)-17 A,CXCL12,s E-SLT,C reactive protein(CRP),IL-6,dyspnea score(m MRC)and adverse drug reactions in two groups were observed.Results After treatment,the total effective rates in treatment group and control group were 89.13%(41 cases/46 cases),69.57%(32 cases/46 cases),with significant difference(P<0.05).The forced expiratory volume in one second(FEV1)and FEV1/forced vital capacity(FVC)in treatment group were(2.33±0.52)L and(64.41±6.93)%,had significant difference with those in control group,which were(2.00±0.25)L and(55.73±5.44)%(P<0.05).The levels of serum IL-17 A,CXCL12,s E-SLT,CRP and IL-6 in treatment group were(23.75±3.35)pg·mL^-1,(173.68±12.99)pg·mL^-1,(16.88±1.19)μg·L^-1,(8.20±1.18)mg·L^-1,(9.48±2.22)pg·mL^-1,all had significant difference with those in control group,which were(35.02±3.40)pg·m L^-1,(192.41±18.21)pg·mL^-1,(20.49±1.95)μg·L-1,(12.32±8.20)mg·L^-1,(14.97±2.01)pg·mL^-1(allP<0.05).The m MRC scorein treatment group and control group were 1.00±0.37,1.93±0.25,with significant difference(P<0.05).During the treatment,there were 1 case of palpitations,2 cases of headache,2 cases nausea and vomiting and 1 case of insomnia in treatment group,with the incidence of 13.04%(6 cases/46 cases).There were 2 cases of heart palpitations and 2 cases of headach

关 键 词：慢性阻塞性肺疾病 血必净注射液 肺功能 

分 类 号：R974[医药卫生—药品]